Clearance of hepatitis C virus after newly acquired infection in injection drug users

被引：59

作者：

Jauncey, M

Micallef, JM

Gilmour, S

Amin, J

White, PA

Rawlinson, W

Kaldor, JM

van Beek, I

Dore, GJ

机构：

[1] Univ New S Wales, Kirketon Rd Ctr, SE Sydney Area Hlth Serv, Sydney, NSW, Australia

[2] Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia

[3] Univ New S Wales, Fac Sci, Sch Biotechnol & Biomol Sci, Sydney, NSW, Australia

[4] Prince Wales Hosp, Dept Microbiol, Div Virol, Sydney, NSW, Australia

[5] New S Wales Dept Hlth, New S Wales Publ Hlth Officer Training Program, Sydney, NSW, Australia

来源：

JOURNAL OF INFECTIOUS DISEASES | 2004年 / 190卷 / 07期

关键词：

D O I：

10.1086/423943

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A retrospective cohort of injection drug users with newly acquired hepatitis C virus (HCV) infection was established to examine viral clearance. Newly acquired HCV infection was defined by anti-HCV antibody seroconversion within a 2-year interval. Stored serum samples were tested for HCV RNA, with viral clearance defined as greater than or equal to2 consecutive negative HCV RNA test results after infection. Ninety-nine cases of HCV infection were identified; 57 had greater than or equal to2 HCV RNA test results after infection. Viral clearance occurred in 24 (42%) cases, with Kaplan-Meier estimated probabilities of 23%, 38%, and 40% at 6, 12, and 24 months, respectively.

引用

页码：1270 / 1274

页数：5

共 50 条

[41] Prevalence of hepatitis C infection in injection drug users in Hong Kong
Lee, S. S.
[J]. HONG KONG MEDICAL JOURNAL, 2009, 15 (06) : 45 - 46
[42] Lack of Behavior change after disclosure of hepatitis C virus infection among young injection drug users in Baltimore, Maryland
Ompad, DC
Fuller, CM
Vlahov, D
Thomas, D
Strathdee, SA
[J]. CLINICAL INFECTIOUS DISEASES, 2002, 35 (07) : 783 - 788
[43] Community-based molecular epidemiology study of hepatitis C virus infection in injection drug users
Chan, D. P. C.
Lee, K. C. K.
Lee, S. S.
Tan, T. Y.
[J]. HONG KONG MEDICAL JOURNAL, 2017, 23 (04) : 27 - 30
[44] Risk factors for hepatitis C virus infection seroconversion in a cohort of Seattle injection drug users.
Hagan, H
Thiede, H
Weiss, NS
Hopkins, S
Duchin, JS
Alexander, ER
[J]. HEPATOLOGY, 1999, 30 (04) : 480A - 480A
[45] Follow-up studies of treatment for hepatitis C virus infection among injection drug users
Dalgard, O
[J]. CLINICAL INFECTIOUS DISEASES, 2005, 40 : S336 - S338
[46] Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users
Grebely, Jason
Raffa, Jesse D.
Meagher, Caite
Duncan, Fiona
Genoway, Krista A.
Khara, Milan
McLean, Mark
Mead, Annabel
Viljoen, Mark
devlaming, Stanley
Fraser, Chris
Conway, Brian
[J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 22 (09) : 1519 - 1525
[47] Hepatitis C virus core antigen reliably diagnoses HCV infection in injection and non-injection drug users
Zeremski, Marija
Chen, Yang
Zavala, Roberto
de Jong, Ype
Sylvester, Clewert
Cloherty, Gavin
Talal, Andrew
[J]. DRUG AND ALCOHOL DEPENDENCE, 2017, 171 : E223 - E223
[48] Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment
Thorpe, LE
Ouellet, LJ
Hershow, R
Bailey, SL
Williams, IT
Williamson, J
Monterroso, ER
Garfein, RS
[J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2002, 155 (07) : 645 - 653
[49] Co-infection of human immunodeficiency virus, hepatitis C and hepatitis B virus among injection drug users in Drop in centers
Javadi, Abbasali
Ataei, Behrooz
Kassaian, Nazila
Nokhodian, Zary
Yaran, Majid
[J]. JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2014, 19 : S17 - S21
[50] Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfection
Dore, GJ
Thomas, DL
[J]. SEMINARS IN LIVER DISEASE, 2005, 25 (01) : 18 - 32

← 1 2 3 4 5 →